Bone, Skin, and Connective Tissue
How dietary silicon supports collagen synthesis, bone mineral density, and the health of skin, hair, and nails — and what the research actually shows
Silicon is the second most abundant element in the earth's crust, yet most people have never considered it a nutrient. In the body, silicon — absorbed primarily as orthosilicic acid — concentrates in connective tissue, bones, skin, hair, and nails, where it plays a structural role in collagen formation and the cross-linking of key proteins [1]. A large study of nearly 2,850 people found that higher dietary silicon intake was associated with meaningfully greater bone mineral density, particularly in men and premenopausal women [1]. Clinical trials with bioavailable silicon supplements have shown benefits for skin elasticity, nail brittleness, and hair fragility [2]. Silicon is found naturally in oats, barley, green beans, bananas, and horsetail herb — though bioavailability varies widely across food sources and supplement forms.
How Silicon Works in the Body
Silicon exists in nature primarily as silica (silicon dioxide, SiO₂) and silicates, but the body absorbs it as monomeric orthosilicic acid (Si(OH)₄) — a small, water-soluble molecule that enters the bloodstream through the small intestine and concentrates in tissues with the highest connective tissue content. It is then excreted by the kidneys, making it a dynamically cycling nutrient rather than one that accumulates passively over decades.
Collagen and Connective Tissue
Silicon's most important biological role appears to be in collagen synthesis and cross-linking. Collagen fibres need to be woven together by cross-links to achieve their characteristic tensile strength — in bone, this gives the collagen matrix the flexibility that prevents brittle fracturing, while in skin it maintains elasticity. Silicon is thought to activate prolyl hydroxylase, the enzyme that modifies proline residues essential for collagen triple-helix stability. In vitro studies have shown that silicon stimulates type I collagen synthesis in fibroblasts — the cells responsible for maintaining skin and tendon structure [4].
Silicon also interacts with glycosaminoglycans (GAGs) — molecules like hyaluronic acid and chondroitin sulfate that form the gel-like matrix of cartilage and skin. Silicon forms bridges between collagen and GAGs, contributing to the composite mechanical properties of these tissues. This is likely why silicon concentrates heavily in areas of active connective tissue turnover: the aorta, trachea, tendons, bone, and skin [5].
Bone Mineral Density
The Framingham Offspring study — one of the largest and longest-running musculoskeletal cohort studies in the world — assessed dietary silicon intake in 2,847 adults and compared it with bone mineral density measured at the hip and spine [1]. The findings were significant: higher silicon intake was positively and independently associated with bone mineral density at all hip sites in men and in premenopausal women. The association was not significant in postmenopausal women, suggesting that estrogen status modifies silicon's bone effects — a pattern that mirrors calcium and vitamin D research.
The proposed mechanism is that silicon promotes osteoblast activity (bone formation) while inhibiting osteoclast activity (bone resorption), shifting the bone remodeling balance toward net deposition [3][5]. Silicon also appears to enhance mineralisation of the osteoid — the protein scaffold of bone — by facilitating calcium phosphate crystal nucleation.
Skin, Hair, and Nails
A randomised, double-blind, placebo-controlled trial by Barel et al. (2005) tested choline-stabilised orthosilicic acid (ch-OSA) at 10 mg silicon per day over 20 weeks in women with photodamaged facial skin [2]. The supplement group showed significant improvements in skin surface microrelief (fine line depth and texture), skin elasticity, nail brittleness, and hair fibre structure. The authors attributed these findings to silicon's role in dermal collagen synthesis and glycosaminoglycan cross-linking.
The bioavailability of different silicon forms matters enormously [4]. Orthosilicic acid — the form absorbed from food and present naturally in the body — has absorption close to 50%, making it by far the most bioavailable form. Silica gel, plant silica (amorphous), and horsetail extract have much lower absorption, often below 5%. This is why studies using purified orthosilicic acid or ch-OSA show stronger results than those using horsetail or silica powders.
Food Sources
Silicon is present across a wide range of plant foods, though bioavailability varies:
- Highest: Oats (especially oat bran), barley, brown rice, beer (fermented from silica-rich grains)
- Good sources: Bananas, green beans, spinach, silica-rich mineral water
- Moderate: Root vegetables, wheat, maize
- Horsetail herb (Equisetum arvense): traditionally used as a silica source; contains 5–8% silica by weight, but mostly in poorly absorbed polymeric forms
Dietary intake in Western populations typically runs 20–50 mg per day, predominantly from cereal grains and drinking water. People eating more whole grains and vegetables generally have higher silicon intakes.
Supplemental Silicon
When supplementing, form determines outcome:
- Choline-stabilised orthosilicic acid (ch-OSA): The most studied bioavailable form; 5–10 mg silicon per day was used in clinical trials for skin and bone outcomes
- Monomethylsilanetriol (MMST): Another bioavailable organic silicon form used in some European products
- Horsetail extract: Widely sold but poorly absorbed; large doses needed for meaningful silicon delivery
- Silica gel or amorphous silica: Used in some food products; absorption is low
Silicon supplements are generally well-tolerated at doses tested in clinical trials. The main caution is for people with kidney disease, as silicon is renally excreted and may accumulate in renal impairment.
See our Collagen page for more on the structural proteins that silicon helps build. For dietary minerals that work alongside silicon in bone metabolism, see our Magnesium page and Vitamin K2 page.
Evidence Review
Bone Mineral Density: Framingham Offspring Cohort
The foundational human study on dietary silicon and bone was published in 2004 by Jugdaohsingh and colleagues (PMID 14969400) [1], using the Framingham Offspring cohort — the children of participants in the original Framingham Heart Study, providing a large, well-characterised sample.
Study design: Cross-sectional analysis of 2,847 participants (1,251 men, 1,596 women). Dietary silicon intake was assessed by food frequency questionnaire with validated nutrient composition data. Bone mineral density was measured by dual-energy X-ray absorptiometry (DXA) at four hip sites and the lumbar spine.
Key findings:
- Silicon intake was positively and significantly correlated with BMD at all hip sites in men (p < 0.05 after multivariate adjustment for age, height, weight, physical activity, alcohol, smoking, and calcium intake)
- In premenopausal women, the same positive association held at all hip sites (p < 0.05)
- In postmenopausal women, no significant association was found — consistent with estrogen's role in silicon-mediated bone formation pathways
- The highest quartile of silicon intake versus the lowest showed BMD differences of approximately 0.1 g/cm² at the femoral neck — a magnitude clinically relevant to fracture risk
Limitations: Cross-sectional design cannot establish causation; dietary assessment by questionnaire introduces measurement error; silicon intake is correlated with overall whole-grain and vegetable consumption, raising confounding concerns despite statistical adjustments.
Silicon Supplementation and Bone Formation Markers: The Spector Trial
Spector et al. (2008; PMID 18547426) conducted a 12-month randomised, placebo-controlled trial in 136 osteopenic women (lumbar spine T-score < −1.5), all of whom received 1,000 mg calcium and 20 µg vitamin D3 daily as a base [3]. Three doses of ch-OSA (3, 6, and 12 mg Si/day) were compared against placebo.
Primary outcomes:
- PINP (N-terminal propeptide of type I procollagen): A specific marker of type I collagen formation — the primary structural protein of bone — significantly increased at 12 months with the 6 mg and 12 mg Si doses versus placebo (p < 0.05)
- Femoral neck BMD: Post-hoc subgroup analysis in women with femoral T-score below −1 showed significant improvement at 6 mg/day
Interpreting the results: The trial was not powered to detect fracture endpoint differences; it was designed as a biomarker study. The finding that PINP — a highly specific bone formation marker — increased suggests that silicon was stimulating osteoblast activity and type I collagen synthesis beyond what calcium and vitamin D alone provided. The dose-response was not linear, with 6 mg appearing optimal over 12 mg in this population.
Limitations: Moderate sample size at 136 completers; the BMD finding came from a post-hoc subgroup, weakening the inference; osteopenic rather than severely osteoporotic participants only.
Skin, Nails, and Hair: The Barel Clinical Trial
Barel et al. (2005; PMID 16205932) conducted a placebo-controlled, double-blind trial of ch-OSA (10 mg Si/day) over 20 weeks in women with photodamaged facial skin [2]. Participants were assessed at baseline, 10 weeks, and 20 weeks using validated objective instruments.
Methodology: Skin surface microrelief was measured by silicone replica imaging — an objective technique capturing fine line depth and texture. Skin mechanical properties (elasticity, extensibility) were assessed by cutometry. Hair and nail changes were assessed by questionnaire and clinician evaluation.
Results:
- Skin surface microrelief improved significantly in the ch-OSA group versus placebo (p < 0.05) by week 20
- Skin mechanical properties — specifically elasticity — improved significantly
- Nail brittleness was reduced in the treatment group (clinician-assessed, p < 0.05)
- Hair showed improved morphological structure on scanning electron microscopy
Mechanism interpretation: The authors attributed findings to silicon's role in dermal collagen synthesis and cross-linking, alongside its effects on glycosaminoglycans that determine skin hydration and mechanical resilience.
Limitations: Single-centre study; relatively short duration (20 weeks); photodamaged rather than general healthy population; no long-term follow-up to assess durability of benefits.
Silicon Forms and Bioavailability
Araújo, Addor, and Campos (2016; PMID 27438201) reviewed the literature on silicon's effects on skin and hair with specific attention to absorption differences between forms [4]:
- Orthosilicic acid (monomeric): Approximately 50% absorption — by far the highest of any silicon form
- Colloidal silicic acid: Bioavailability drops sharply as polymer chain length increases; below 5% for most polymerised forms
- Horsetail extracts: Contain silicic acid partially as poorly soluble polymers and silica-containing structural components; bioavailability in the low single digits
- Silicon from grain foods: Well-absorbed at approximately 40–50% when present as monomeric silicic acid; much less so from plant structural components (cell walls)
The review also identified a gap in direct head-to-head comparisons of different silicon forms in clinical outcomes — most positive trials have used orthosilicic acid or ch-OSA specifically, making it difficult to generalise to other supplement forms commonly sold.
Umbrella Review: 2024 Evidence Summary
Pritchard and Nielsen (2024; PMID 38337624) published an umbrella review of systematic reviews on silicon and bone health, specifically examining whether animal data could inform human dosing [5].
Key findings:
- Across animal and human studies, silicon consistently and positively influenced bone and mineral metabolism
- Animal dose thresholds for bone effects, when translated to human equivalents, would require impractically high intakes — suggesting different mechanisms may be rate-limiting in humans than in rodent models
- In combination with vitamin D and calcium, supplemental silicon positively influenced bone turnover markers and increased femoral BMD in postmenopausal women across the reviewed literature
- The reviewers concluded that silicon is an underappreciated bone-supportive micronutrient and called for standardised dose-ranging trials in humans to establish clinical guidelines
Overall evidence strength: The mechanistic case for silicon in bone and connective tissue is strong and supported by multiple independent pathways. Human clinical trial evidence supports a role in bone formation biomarkers and skin quality. The key gaps are long-term fracture outcome data (which would require multi-year trials) and direct comparisons against established interventions like calcium and vitamin D. Silicon is best understood as a synergistic micronutrient — not a replacement for foundational bone health practices, but a plausible supporting actor whose role has been underappreciated in clinical nutrition guidelines.
References
- Dietary silicon intake is positively associated with bone mineral density in men and premenopausal women of the Framingham Offspring cohortJugdaohsingh R, Tucker KL, Qiao N, Cupples LA, Kiel DP, Powell JJ. Journal of Bone and Mineral Research, 2004. PubMed 14969400 →
- Effect of oral intake of choline-stabilized orthosilicic acid on skin, nails and hair in women with photodamaged skinBarel A, Calomme M, Timchenko A, De Paepe K, Rogiers V, Vanden Berghe D. Archives of Dermatological Research, 2005. PubMed 16205932 →
- Choline-stabilized orthosilicic acid supplementation as an adjunct to calcium/vitamin D3 stimulates markers of bone formation in osteopenic females: a randomized, placebo-controlled trialSpector TD, Calomme MR, Anderson SH, Clement G, Bevan L, Demeester N, Swaminathan R, Campion GV, Vanden Berghe DA, Tucker KL. BMC Musculoskeletal Disorders, 2008. PubMed 18547426 →
- Use of silicon for skin and hair care: an approach of chemical forms available and efficacyAraújo LA, Addor F, Campos PM. Anais Brasileiros de Dermatologia, 2016. PubMed 27438201 →
- Silicon Supplementation for Bone Health: An Umbrella Review Attempting to Translate from Animals to HumansPritchard JM, Nielsen T. Nutrients, 2024. PubMed 38337624 →
Transparency
View edit historyEvery change to this page is tracked in version control. If you have conflicting research or think something is wrong, we want to hear about it.